课题基金 / 基金详情

Role of ASXL1 in normal and abnormal granulopoiesis.

Role of ASXL1 in normal and abnormal granulopoiesis.
ASXL1 在正常和异常粒细胞生成中的作用。
批准号:
10594440
负责人:
Julia E Maxson
金额:
$47.98万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-04-01 至 2026-03-31

项目摘要

项目成果

Julia E Maxson的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY ASXL1 is an epigenetic regulatory protein that is frequently mutated in myelodysplastic syndromes and myeloproliferative neoplasms. Mutations in ASXL1 are associated with treatment resistance and poor prognosis. ASXL1 mutations are highly enriched in CSF3R- mutant myeloproliferative neoplasms, disorders characterized by an increased production of neutrophils. Despite the high frequency of ASXL1 mutations and association with poor prognosis, there is little known about the function of ASXL1 in normal or abnormal neutrophil production. Through single cell RNA sequencing, we identified an essential role for ASXL1 in normal neutrophil development. In this context, deletion of ASXL1 perturbs RNA polymerase II function and activates a Myc signaling network in the neutrophil progenitor population. The goal of this proposal is to define the molecular mechanisms by which ASXL1 controls the neutrophil developmental program, and to understand how truncating mutations in ASXL1 contribute to the biology of myeloproliferative disorders. Our long-term objective is to use this mechanistic understanding to develop therapeutic interventions that reverse the defects in neutrophil development associated with ASXL1 mutations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of ASXL1 in normal and abnormal granulopoiesis.
Mechanisms of differentiation blockade in CSF3R-mutant AML
Role of ASXL1 in normal and abnormal granulopoiesis.
Mechanisms of differentiation blockade in CSF3R-mutant AML
海外基金